CD4 and acute myeloid leukemia: In conclusion, IL-1RAP CAR T cells produced from CD4+ and CD8+ selected cells and carrying an iCASP9 safety switch will strengthen the safety of our CAR T cell immunotherapy and will be applied in a future phase I clinical trial in AML.